中草药治疗系统性红斑狼疮:随机安慰剂对照试验的系统评价与Meta分析
该系统评价纳入13项随机安慰剂对照试验共856例系统性红斑狼疮患者,评价中草药单用或联合常规治疗的疗效与安全性。Meta分析显示中草药可显著降低SLEDAI评分、中医证候积分、糖皮质激素用量及血沉,并升高补体C4,不良事件与安慰剂无显著差异。
要点
- 中草药可显著降低SLE疾病活动度(SLEDAI)及中医证候积分。
- 中草药有助于减少糖皮质激素用量并改善血沉和补体C4。
- 中草药不良事件发生率与安慰剂无显著差异。
核心结论
- 中草药对控制SLE疾病活动及减少糖皮质激素用量有显著益处。
研究设计与样本
- 系统评价与Meta分析,检索7个数据库至2020年8月16日,纳入13项RCT共856例患者。
主要发现
- 与安慰剂相比,中草药降低SLEDAI评分(MD=-1.74,95%CI:-2.29至-1.18)。
- 中草药降低中医证候积分(SMD=-0.89,95%CI:-1.16至-0.62)。
- 中草药减少糖皮质激素用量(MD=-2.41 mg/d,95%CI:-3.34至-1.48)。
- 中草药降低血沉(MD=-4.78 mm/h,95%CI:-8.86至-0.71)。
- 中草药升高血清补体C4水平(MD=0.03 mg/dL,95%CI:0.00至0.06)。
关键数值与推荐
- 不良事件发生率在中草药与安慰剂之间无显著差异。
临床怎么用
- SLE患者可考虑在常规治疗基础上联用中草药以控制疾病活动并减少激素用量。
局限性
- 未来亟需多中心、更长随访且设计更严谨的RCT验证中草药治疗中重度SLE的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide evidence on the efficacy and safety of Chinese herbal medicine (CHM) as interventions for systemic lupus erythematosus (SLE). METHODS: Seven electronic databases, including the Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), Chinese Biomedical Literature Service System (SinoMed), Wanfang, Embase, and PubMed, were comprehensively searched, from their inception to August 16, 2020, for all randomized controlled trials (RCTs) that focused on CHM used alone or in combination with conventional medicine for SLE. Outcomes were SLE activity index (SLEDAI), traditional Chinese medicine symptom/syndrome score (TCMSS), dosage of glucocorticoids, main serological testing, and incidence of adverse events. Data were extracted and pooled using Review Manager 5.3 software. RESULTS: A total of 13 RCTs enrolling 856 participants met our inclusion criteria. Meta-analyses showed that, compared to placebo, CHM had statistically significant effect on reducing SLEDAI score (MD=-1.74, 95% CI: -2.29 to -1.18), diminishing TCMSS (SMD=-0.89, 95% CI: -1.16 to -0.62), decreasing dosage of glucocorticoids (MD=-2.41 mg/d, 95% CI: -3.34 to -1.48), lowering erythrocyte sedimentation rate (MD=-4.78 mm/h, 95% CI: -8.86 to -0.71), and increasing serum complement C4 level (MD=0.03 mg/dL, 95% CI: 0.00 to 0.06). No significant difference was found between CHM and placebo on adverse events. CONCLUSIONS: CHM provided significant beneficial effect on controlling disease activity and reducing dose of glucocorticoids used among SLE patients. Future advanced designed RCTs for CHM treating moderate to severe SLE with multicenter and longer follow-up are urgently needed.
引用
- Wang Y, Han M, Pedigo CE, et al. Chinese Herbal Medicine for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized, Placebo-Controlled Trials. Chin J Integr Med. 2021. PMID: 34319503. doi:10.1007/s11655-021-3497-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。